Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Precipio, Inc.
  6. Summary
    PRPO   US74019L5030

PRECIPIO, INC.

(PRPO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
1.07(c) 1.08(c) 1.11(c) 1.12(c) 1.16(c) Last
104 750 843 897 98 631 63 269 64 301 Volume
0.00% +0.93% +2.78% +0.90% +3.57% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 20,9 M - -
Net income 2022 -4,82 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,52x
Yield 2022 -
Sales 2023 37,0 M - -
Net income 2023 0,12 M - -
Net Debt 2023 - - -
P/E ratio 2023 116x
Yield 2023 -
Capitalization 26,3 M 26,3 M -
Capi. / Sales 2022 1,26x
Capi. / Sales 2023 0,71x
Nbr of Employees 56
Free-Float 96,8%
More Financials
Company
Precipio, Inc. is a healthcare solutions company that is focused on cancer diagnostics. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells,... 
Read more
More about the company
Ratings of Precipio, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about PRECIPIO, INC.
05/24Precipio Shares Rise on Regulatory Approval for Sale of Screening Technology in Europea..
MT
05/24Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe
AQ
05/11PRECIPIO, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
05/11Precipio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Precipio Signs First IV-Cell Customer Agreement
AQ
05/10Precipio Signs First IV-Cell Customer Agreement
CI
04/26Precipio customer American Oncology Network (AON) selected to present HemeScreen® techn..
AQ
04/04TRANSCRIPT : Precipio, Inc., Q4 2021 Earnings Call, Apr 04, 2022
CI
03/30PRECIPIO, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
03/30Precipio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/23PRECIPIO : Announces 2021 Fourth Quarter and Year-End Shareholder Update Call - Form 8-K
PU
03/23PRECIPIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
03/22Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call
AQ
03/21PRECIPIO : Announces the Resignation of its Chief Financial Officer and Appointment of Int..
PU
03/21PRECIPIO, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Fina..
AQ
More news
News in other languages on PRECIPIO, INC.
05/24Les actions Precipio augmentent suite à l'approbation réglementaire de la vente de la t..
05/11Precipio, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/10Precipio signe le premier accord avec un client de IV-Cell
03/30Precipio, Inc. annonce ses résultats pour l'année complète se terminant le 31 décembre ..
03/21Le directeur financier de Precipio démissionne ; Matt Gage est nommé directeur financie..
More news
Analyst Recommendations on PRECIPIO, INC.
More recommendations
Chart PRECIPIO, INC.
Duration : Period :
Precipio, Inc. Technical Analysis Chart | PRPO | US74019L5030 | MarketScreener
Technical analysis trends PRECIPIO, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,16 $
Average target price 4,00 $
Spread / Average Target 245%
EPS Revisions
Managers and Directors
Ilan Danieli Chief Executive Officer & Director
Matthew Gage CFO, Director-Financial Report & Analysis
Richard Alvin Sandberg Chairman
Ayman A. Mohamed Vice President-Research & Development
Ahmed Zaki Sabet Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
PRECIPIO, INC.-26.58%26
SARTORIUS AG-31.06%25 907
REVENIO GROUP OYJ-13.27%1 371
BIOTAGE AB (PUBL)-23.66%1 341
VAREX IMAGING CORPORATION-27.42%912
CELLAVISION AB (PUBL)6.24%838